• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

Self-Amplifying RNA: A New Era in mRNA Vaccine Technology

  • October 1, 2024
  • Pharma & Biotech
Self-amplifying RNA (saRNA) offers enhanced immunity, cost benefits, and innovative delivery in mRNA vaccines, revolutionizing global health strategies.
Continue Reading
VASRO GmbH

Debt vs. Equity: Impacts on ROI Explained

  • September 30, 2024
  • Pharma & Biotech, Tech
Understand how debt vs. equity impacts ROI. Explore capital structure optimization to balance financial health and maximize returns.
Continue Reading
VASRO GmbH

Introduction to equity valuation and financial analysis

  • September 27, 2024
  • Pharma & Biotech, Tech
Gain insights into stock valuation and financial analysis. Learn about valuation methods, financial reports and the importance of return and risk.
Continue Reading
VASRO GmbH

Analyzing the DAX Index: Insights into German Stock Trends

  • September 26, 2024
  • Pharma & Biotech, Tech
Gain insights into the DAX Index and German stock trends. Explore economic influences, sector performance, and investment strategies for future growth.
Continue Reading
VASRO GmbH

The Influence of Economic Indicators on Stock Market Movements

  • September 25, 2024
  • Pharma & Biotech, Tech
Understand how GDP, inflation, and other economic indicators influence stock market trends and investor strategies for risk management.
Continue Reading
VASRO GmbH

Essential Investment Strategies for Portfolio Excellence

  • September 24, 2024
  • Pharma & Biotech, Tech
Master essential investment strategies for portfolio excellence. Learn about diversification, asset allocation, and risk management for optimal results.
Continue Reading
VASRO GmbH

Exploring Equity Valuation Techniques: Insights from VASRO GmbH

  • September 23, 2024
  • Pharma & Biotech, Tech
Explore equity valuation techniques with insights from VASRO GmbH. Learn about DCF, comparable analysis, and innovative approaches in financial analysis.
Continue Reading
VASRO GmbH

The Impact of Apple’s AI Innovations on Its Stock Performance

  • September 20, 2024
  • Tech
Apple Inc.'s AI innovations boost stock performance by enhancing iPhone features, health apps, and market positioning. Explore investment opportunities and future prospects.
Continue Reading
VASRO GmbH

Big Pharma M&A: Key Deals Shaping 2023 and 2024

  • September 19, 2024
  • Pharma & Biotech
Explore key pharma M&A deals shaping 2023-2024, including Pfizer's $43B Seagen merger. Discover market dynamics, future trends, and industry impacts.
Continue Reading
VASRO GmbH

Why Blockbuster Drugs Status Transforms Markets

  • September 18, 2024
  • Pharma & Biotech
Explore how blockbuster drugs status reshapes markets, driving revenue growth, innovation, and industry dynamics while addressing challenges like patent expirations.
Continue Reading

Posts pagination

Previous 1 … 35 36 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.